$ARVN

ARVINAS, INC. (ARVN): Submission of Matters to a Vote of Security Holders

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. arvn-20260624 0001655759 FALSE 0001655759 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep

Original reporting
Published Jun 25, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ARVN
Neutral
high confidence
Mentioned
$ARVN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARVNNeutralLow
01

Why it matters

The disclosure confirms governance items were approved (including say-on-pay on a non-binding basis) and Deloitte & Touche LLP was ratified as auditor for FY ending Dec. 31, 2026.

02

Market read

This is a routine corporate governance update; it is unlikely to drive a material repricing absent additional context not included here.

03

What to watch

The filing does not provide director vote margins, compensation details, or any indication of contested governance—so trading impact should be minimal.

Relevance 6/10Novelty 2/10Timing: filed after-hours on 2026-06-25 for the 2026-06-24 annual meeting

Background

The company’s 8-K (Item 5.07) summarizes final shareholder voting results from its annual meeting held June 24, 2026.

Company-level read

Ticker impact

$ARVNNeutralHigh confidence
Context

Arvinas filed an 8-K reporting annual meeting vote results, including election of two Class II directors and advisory say-on-pay approval.

Expected impact

Limited near-term impact; any reaction likely muted unless investors were focused on governance outcomes.

Evidence & confidence

The filing is a standard Item 5.07 disclosure of voting results (board election, advisory compensation vote, auditor ratification) without new strategy, earnings, or regulatory developments.

Market effects

None; governance vote results do not change sector fundamentals.

None indicated; single-company corporate filing.

None; no cross-border transaction or regulatory action described.

Counterpoint

If investors were concerned about board composition or executive compensation, the vote totals could reduce uncertainty, but the disclosure still lacks new fundamentals.

Key entities

  • Arvinas, Inc.

    Nasdaq-listed issuer filing the 8-K with annual meeting voting results.

  • Leslie V. Norwalk, Esq.

    Elected Class II director for a term until the 2029 annual meeting.

  • Randy Teel, Ph.D.

    Elected Class II director for a term until the 2029 annual meeting.

  • Deloitte & Touche LLP

    Ratified by stockholders as independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

$ARVNMedAI 8/10

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas (ARVN) will present Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 targets LRRK2, a protein linked to Parkinson’s and PSP. The presentations will include biomarker and oculomotor data. Arvinas is a clinical-stage biotech company focused on protein degradation therapies.

$ARVNHighAI 9/10

Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod

Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.

$ARVNMedAI 8/10

Arvinas (ARVN) Q2 2026 Earnings Call Transcript

Arvinas (ARVN) reported Q2 2026 revenue of $249.7 million, including $62.5 million from a Rigel license and a $50 million Pfizer (PFE) milestone tied to FDA approval of VEPPANU. Net income was $169.4 million and diluted EPS $2.58. Cash and marketable securities were $567.9 million, funding into 2H 2028. The call also discussed clinical timing updates and an FDA-requested delay for ARV-102.

$ARVNMedAI 8/10

Why is Arvinas stock surging today?

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.